A61K 40/4225
Growth factors
Official title: {Growth factors}
A61K40/4225 (Growth factors) appears on 42 US grants and 126 published applications in this corpus.
Search patents in A61K- Granted patents
- 42
- Published applications
- 126
- Assignees
- 69
- Inventors
- 272
- Latest grant
- 8 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 0 | 1 |
| 2003 | 0 | 2 |
| 2004 | 1 | 3 |
| 2005 | 0 | 0 |
| 2006 | 0 | 2 |
| 2007 | 0 | 0 |
| 2008 | 1 | 5 |
| 2009 | 0 | 0 |
| 2010 | 0 | 2 |
| 2011 | 0 | 1 |
| 2012 | 0 | 1 |
| 2013 | 1 | 2 |
| 2014 | 0 | 2 |
| 2015 | 1 | 0 |
| 2016 | 1 | 2 |
| 2017 | 0 | 3 |
| 2018 | 1 | 6 |
| 2019 | 2 | 7 |
| 2020 | 2 | 10 |
| 2021 | 7 | 12 |
| 2022 | 4 | 12 |
| 2023 | 6 | 15 |
| 2024 | 3 | 11 |
| 2025 | 7 | 15 |
| 2026 | 5 | 12 |
By publication year. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Transforming growth factor beta-resistant natural killer cells8 Sep 2026US 12,729,228 B2Research Institute At Nationwide Children's Hospital
- Fusion constructs and methods of using thereof11 Aug 2026US 12,703,747 B2Precigen, Inc.
- Engineered T cells31 Mar 2026US 12,590,136 B2Medigene Immunotherapies GmbH
- Bi-specific chimeric antigen receptor31 Mar 2026US 12,590,145 B2The Regents of the University of California
- GPC3 binding molecules3 Feb 2026US 12,540,196 B2Kite Pharma, Inc.
- Methods for enhancing tcrab+ cell depletion efficiency17 Sep 2026US 2026/0274949 A1Allogene Therapeutics, Inc.
- Gpc3 binding molecules20 Aug 2026US 2026/0242507 A1Kite Pharma, Inc.
- Anti-vegfa fusion protein, and preparation method therefor and use thereof13 Aug 2026US 2026/0234232 A1Quaerite Biopharm Research (Beijing) Co., Ltd.
- Armored immunoresponsive cells targeting dll3 and uses thereof6 Aug 2026US 2026/0224629 A1Memorial Hospital for Cancer and Allied Diseases
- Bi-specific chimeric antigen receptor23 Jul 2026US 2026/0209329 A1The Regents of the University of California
Most cited
By later US patents
- Antibody constructs for DLL3 and CD338US 10,294,300 B2Amgen Research (Munich) GmbH · 2019
- Methods of treating aging-related disorders15US 11,672,826 B2HCW Biologics, Inc. · 2023
- Methods for stimulating proliferation or differentiation of an immune cell with a multi-chain chimeric polypeptide15US 11,730,762 B2HCW Biologics, Inc. · 2023
- Method to prevent graft rejection using TGF-beta to induce T suppressor cells13US 6,759,035 B2University of Southen California · 2004
- Methods and compositions for enhancing the therapeutic effect of anti-tumor T cells12US 9,226,936 B2The Wistar of Anatomy and Biology · 2016